

Biotransformation of Drugs (Drug Metabolism)

Tuesday, October 14, 2025 7:06 PM

◆ Definition

Biotransformation (also called drug metabolism) refers to the chemical modification of a drug within the body to facilitate its inactivation, activation, or excretion.

◆ Importance (Pharmacokinetic relevance)

Biotransformation determines:

- Duration of drug action
- Rate of elimination
- Toxicity or safety profile

◆ Outcomes of Biotransformation

☐ Inactivation → Drug converted to inactive form → Excreted

☐ Activation → Conversion of prodrug to active form

→ Formation of toxic metabolites → Adverse effects

Sites of Biotransformation

Site	Major Drugs Metabolized
Liver	Paracetamol, Prazosin, Morphine, Nitroglycerine, Propranolol
GIT	Catecholamines, Chlorpromazine, Salbutamol
Lungs	Prostaglandins
Plasma	Suxamethonium
Skin / Kidneys / Adrenals	Minor sites for metabolism

Types of Biotransformation

1. Non-Enzymatic (Spontaneous)

- Occurs without enzymes.
- Due to molecular rearrangement in body fluids.
- Example: Hofmann elimination → *Atracurium*, *Mustine HCl*

2. Enzymatic

○ Involves specific enzyme systems:

- Non-microsomal enzymes → Esterases, Amidases, Oxidases, Conjugases

Examples:

- Monoamine Oxidase → *Catecholamines*
- Alcohol Dehydrogenase → *Ethanol*

- Microsomal enzymes → Found in smooth endoplasmic reticulum
-

Microsomal Biotransformation

Occurs in the Endoplasmic Reticulum, forming microsomes during tissue homogenization.

Enzyme System:

Microsomal Mixed Function Oxidase System
(Monooxygenase System)

Also known as Cytochrome P450 system.

✿ Components:

- Cytochrome P450 – Heme protein (main enzyme)
- NADPH-Cytochrome P450 Oxidoreductase – Flavoprotein
- NADPH – Reducing agent
- Oxygen molecule (O_2) – Required for oxidation

🔄 Flowchart: Microsomal Biotransformation Mechanism

Drug + Cytochrome P450 (Fe^{3+})



Complex formation → Drug-P450 (Fe^{3+}) complex



Electron transfer from NADPH via flavoprotein (FAD/FMN)



$Fe^{3+} \rightarrow Fe^{2+}$ (reduction)



Drug + Cytochrome P450 (Fe^{2+})



Oxygen binds to Fe^{2+} -Drug complex → forms activated oxygen complex



Second electron transfer → Oxygen activation



One O-atom → incorporated into drug → oxidized metabolite formed

Other O-atom → combined with hydrogen → H_2O formed



Cytochrome P450 regenerated (enzyme reused) 



Cytochrome P450 (CYP450)

- Hemeprotein enzyme family involved in oxidation of drugs.

- Naming system: e.g. CYP3A4

- Root: CYP
- Family: 3
- Subfamily: A
- Isoform: 4

◆ Genetic Polymorphism:

Some individuals have variable CYP activity → affects drug metabolism (e.g. poor vs extensive metabolizers).

Reactions of Biotransformation

Biotransformation occurs in two phases:

Phase I Reactions (Non-synthetic / Catabolic)

Purpose: Introduce or unmask functional groups (-OH, -COOH, -SH, -NH₂) → makes drug more polar & water-soluble.

Location: Endoplasmic reticulum.

◆ Possible Outcomes

- Inactive metabolite → excreted
- Active metabolite → may undergo phase II or produce pharmacological action
- Toxic metabolite → may cause adverse effects
- Prodrug → activated by phase I

✳ Types of Phase I Reactions

Reaction Type	Subtype / Example
Oxidation	<ul style="list-style-type: none">- Aromatic hydroxylation → <i>Phenobarbitone</i>- Aliphatic hydroxylation → <i>Meprbamate</i>- Dealkylation → <i>Theophylline</i>- N-oxidation → <i>Aniline</i>- S-oxidation → <i>Chlorpromazine</i>- Deamination → <i>Amphetamine</i>- Desulfuration → <i>Parathion</i>
Reduction	<ul style="list-style-type: none">- Azo reduction → <i>Prontosil</i>- Nitro reduction → <i>Chloramphenicol</i>- Carbonyl reduction → <i>Methadone</i>

- Hydrolysis
- Ester hydrolysis → *Procaine*
 - Amide hydrolysis → *Lignocaine*
-

✪ Phase II Reactions (Synthetic / Conjugation)

Purpose: Conjugation of drug (or phase I metabolite) with an endogenous compound, forming polar, inactive, and easily excretable conjugates.

◆ Outcomes


- Drug (Phase I) → Phase II → Excreted
- Some drugs directly undergo Phase II (e.g. Isoniazid)
- Occasionally form active or toxic metabolites

📖 Types of Phase II Reactions

Type of Conjugation	Endogenous Reactant	Enzyme (Transferase)	Example
Glucuronidation	UDP-Glucuronic acid	UDP-Glucuronyl transferase	Morphine

Acetylation	Acetyl-CoA	N-Acetyl transferase	Isoniazid
Glutathione conjugation	Glutathione (GSH)	GSH-S-transferase	Acetaminophen
Glycine conjugation	Glycine	Acyl-CoA glycine transferase	Salicylic acid
Sulfate conjugation	PAPS (3'-phosphoadenosine-5'-phosphosulfate)	Sulfotransferase	Methyldopa
Methylation	S-Adenosyl methionine (SAM)	Methyltransferase	Epinephrine

Flowchart: Overall Drug Biotransformation

Drug (lipid soluble) → *Phase I (Oxidation / Reduction / Hydrolysis)* → Polar metabolite → *Phase II (Conjugation)* → Highly polar metabolite → Excreted via kidneys / bile


Clinical Significance

- Explains drug interactions (e.g. enzyme induction or inhibition)
- Helps understand dose adjustment in hepatic diseases
- Predicts toxicity of metabolites (e.g. acetaminophen)

toxicity via NAPQI)

Factors Affecting Biotransformation of Drugs

◆ I. Enzyme Induction

Definition:

↑ *Drug-metabolizing enzyme activity* due to prolonged drug exposure → increased rate of metabolism.

◆ Mechanism

Prolonged drug administration → ↑ Enzyme synthesis or ↓ degradation → Enhanced metabolism → Reduced plasma concentration of drugs

◆ Common Enzyme Inducers

Phenytoin → CYP450 inducer

Phenobarbital → CYP2B, CYP3A

Rifampicin → Broad CYP inducer

Smoking → Induces CYP1A2

Charcoal-broiled foods / Plasticizers → Induce microsomal enzymes


◆ Clinical Significance


☞ Slow onset (requires days)

☞ Parent drug → Metabolite (↑ rate)

Consequences:

- ⚠ Therapeutic failure: Oral contraceptives + Rifampicin → reduced efficacy
- ☠ Toxicity: Acetaminophen in chronic alcoholics → ↑ NAPQI (hepatotoxic)
- ☞ Auto-induction: Carbamazepine induces its own metabolism
- 🌿 Beneficial effect: Phenobarbital → induces glucuronyl transferase → treats neonatal jaundice

-  Dose adjustment required for drugs with *low therapeutic index* (e.g. warfarin, theophylline)

 Flowchart: Enzyme Induction

Prolonged drug administration \rightarrow \uparrow Enzyme synthesis \rightarrow
 \uparrow Drug metabolism \rightarrow \downarrow Drug concentration \rightarrow
Therapeutic failure / altered efficacy

2. Enzyme Inhibition

Definition:

\downarrow Drug-metabolizing enzyme activity \rightarrow slower biotransformation \rightarrow \uparrow plasma levels.

 Mechanism

Competitive or non-competitive binding to CYP enzymes
 \rightarrow prevents metabolism of other drugs.

 Common Enzyme Inhibitors

Cimetidine

Ketoconazole

Macrolides (e.g. Erythromycin)

Grapefruit juice 🍷

◆ Clinical Significance

→ Rapid onset

→ Parent drug → metabolite (↓ rate)

Consequences:

- ⚠️ ↑ Toxicity risk (due to accumulation)
- ✖️ Competition between drugs for same enzyme
- li>• ☠️ Suicide inhibitors: e.g. *Chloramphenicol* binds irreversibly to enzymes
- li>• 🕒 Dose adjustment required for *narrow therapeutic index* drugs (e.g. phenytoin, warfarin)

🔄 Flowchart: Enzyme Inhibition

Drug A (inhibitor) + Drug B (substrate) \rightarrow \downarrow Enzyme activity \rightarrow \downarrow Drug B metabolism \rightarrow \uparrow Plasma concentration of Drug B \rightarrow Potential toxicity

3. Genetic Variations

Definition:

Differences in enzyme expression due to genetic polymorphisms \rightarrow alter metabolism rate between individuals.

◆ Examples

Enzyme / Gene	Variation	Effect / Drug Example
Pseudocholinesterase	Genetic deficiency	Prolonged action of <i>succinylcholine</i>
CYP2C9 (*1 / *2 / *3)	Polymorphism	Alters <i>warfarin</i> metabolism
CYP2D6 (PM / UM types)	Polymorphism	Affects <i>tamoxifen</i> , <i>amitriptyline</i>
N-acetyltransferase (NAT2)	Fast / slow acetylators	<i>Isoniazid</i> metabolism

🧠 Key Concept:

- Fast metabolizers → ↓ plasma levels → ↓ toxicity risk
- Poor metabolizers → ↑ plasma levels → ↑ toxicity risk

➡ Foundation of pharmacogenetics / personalized medicine

👶👴 4. Age

Extreme age groups show altered biotransformation:

Age Group	Reason	Example / Effect
Neonates / Infants	Immature enzyme systems	<i>Chloramphenicol</i> → gray baby syndrome
Elderly	↓ hepatic blood flow, polypharmacy	↑ sensitivity to <i>diazepam</i> , <i>propranolol</i>

➡ Dose calculation must consider age (mg/kg basis).

S. Gender

- Influenced by basal metabolic rate (BMR) and hormonal levels
 - Drugs: *Salicylates, Benzodiazepines, Propranolol* show variation
 - Pregnancy: Hormonal changes alter metabolism
-

6. Pathological Conditions

Diseases can reduce enzyme activity:

Condition	Effect
Hepatic disease	↓ enzyme synthesis
Cardiovascular disease	↓ hepatic blood flow
Pulmonary disease	↓ oxidation reactions
Thyroid disorders	Alter metabolism rate



7. Diet & Nutritional Status

Dietary Factor	Effect
High protein / vitamin / mineral diet	↑ enzyme activity
Malnutrition	↓ metabolism
Charcoal-broiled foods / Cruciferous vegetables	Enzyme induction
Grapefruit juice	Enzyme inhibition
Chronic alcoholism	Enzyme induction (CYP2E1)



8. Environmental Factors

- Smoking → induces CYP1A2
- Pesticides / Pollutants → alter hepatic enzyme function



9. Racial Differences

Different ethnic groups may show variation in enzyme activity.

E.g. Caucasians, Africans, and Asians differ in CYP2D6 and NAT2 polymorphisms.



10. Drug Interactions

- Competition: Two drugs for same enzyme → inhibition
 - Induction / Inhibition: One drug alters metabolism of the other → therapeutic failure or toxicity
-



11. Chemical Structure of Drug

- The structure determines its metabolic pathway.

- Minor structural differences → major differences in metabolism.
-



12. Drug Dose / Concentration

- High doses may saturate enzyme systems → alternate toxic pathways used.
- Example:

Acetaminophen

- 95% → Glucuronidation / Sulfation (safe)
- ~5% undergoes oxidation via CYP2E1 → forms toxic intermediate → N-acetyl-p-benzoquinone imine (NAPQI) → NAPQI is neutralized by conjugation with Glutathione (GSH) → harmless
- In overdose → GSH depleted → unconjugated NAPQI binds to hepatocellular proteins → cell necrosis → acute liver damage / hepatic failure



💧 13. Route of Administration

First-Pass Metabolism (Pre-Systemic Metabolism)

🧠 Definition:

The metabolism of a drug *before it enters the systemic circulation* — mainly when given orally.

📍 Sites:

- Liver
- Gastrointestinal (GIT) wall

📈 Effect:

Reduces the bioavailability of the drug.

💡 Example:

Nitroglycerine → undergoes extensive first-pass metabolism

➡ therefore administered sublingually to bypass the

liver and reach systemic circulation directly ♥

Flowchart: Summary of Factors Affecting Biotransformation

Drug metabolism rate

← Influenced by →

- Enzyme induction / inhibition
- Genetics
- Age / Gender
- Disease states
- Diet & Environment
- Drug interactions / Dose / Route

↓

Alters → Drug plasma level → Therapeutic efficacy / Toxicity 